Achilles Heel of ETS Fusions
Abstract
In prostate cancer TRMPRSS2-ETS fusions are common, but not readily druggable. Our study aims to discover novel therapeutic targets displaying synthetic lethal (or Achilles' heel) interaction with ETS fusions, using a highly multiplexed RNA interference-based approach. Towards this goal, key accomplishments during the first year include the creation and validation of ETS knockdown and inducible prostate cell lines; the piloting and optimization of pooled shRNA barcode screens; and the completion of the first whole-genome shRNA screens. Future efforts will focus on the completion of screens, analysis of data, and validation of positive hits as genes that are selectively targetable in the context of ETS fusions.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2010
- Accession Number
- ADA540242
Entities
People
- Jonathan R. Pollack
Organizations
- Stanford University